PharmChem, Inc. (PCHM)
USD 2.97
(-3.26%)
USD 2.97
(-3.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 845.1 Thousand USD | -2.91% |
| 2022 | 870.43 Thousand USD | -53.0% |
| 2021 | 1.85 Million USD | -5.56% |
| 2020 | 1.96 Million USD | 14.12% |
| 2019 | 1.71 Million USD | 10.2% |
| 2018 | 1.55 Million USD | 32.33% |
| 2017 | 1.17 Million USD | 16.07% |
| 2016 | 1.01 Million USD | 0.0% |
| 2002 | -1.29 Million USD | 84.73% |
| 2001 | -8.47 Million USD | -722.78% |
| 2000 | 1.36 Million USD | -51.39% |
| 1999 | 2.8 Million USD | 340.94% |
| 1998 | 635 Thousand USD | 150.0% |
| 1997 | -1.27 Million USD | -2860.87% |
| 1996 | 46 Thousand USD | 100.68% |
| 1995 | -6.8 Million USD | -6900.0% |
| 1994 | 100 Thousand USD | 102.56% |
| 1993 | -3.9 Million USD | -269.57% |
| 1992 | 2.3 Million USD | 35.29% |
| 1991 | 1.7 Million USD | 325.0% |
| 1990 | 400 Thousand USD | 144.44% |
| 1989 | -900 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 158.36 Thousand USD | -48.69% |
| 2024 Q2 | 572.4 Thousand USD | 261.45% |
| 2023 Q1 | 135.52 Thousand USD | -41.17% |
| 2023 FY | 845.1 Thousand USD | -2.91% |
| 2023 Q4 | 308.63 Thousand USD | 38.45% |
| 2023 Q2 | 178.02 Thousand USD | 31.36% |
| 2023 Q3 | 222.91 Thousand USD | 25.21% |
| 2022 Q3 | 222.05 Thousand USD | 50.7% |
| 2022 Q1 | 270.67 Thousand USD | -69.02% |
| 2022 Q2 | 147.34 Thousand USD | -45.56% |
| 2022 FY | 870.43 Thousand USD | -53.0% |
| 2022 Q4 | 230.35 Thousand USD | 3.74% |
| 2021 FY | 1.85 Million USD | -5.56% |
| 2021 Q3 | 91.29 Thousand USD | -80.51% |
| 2021 Q2 | 468.37 Thousand USD | 11.84% |
| 2021 Q4 | 873.61 Thousand USD | 856.97% |
| 2021 Q1 | 418.79 Thousand USD | 0.0% |
| 2020 FY | 1.96 Million USD | 14.12% |
| 2019 FY | 1.71 Million USD | 10.2% |
| 2018 FY | 1.55 Million USD | 32.33% |
| 2017 FY | 1.17 Million USD | 16.07% |
| 2016 FY | 1.01 Million USD | 0.0% |
| 2003 Q1 | -878 Thousand USD | -720.56% |
| 2003 Q3 | 818 Thousand USD | 217.7% |
| 2003 Q2 | -695 Thousand USD | 20.84% |
| 2002 Q3 | -983 Thousand USD | -372.6% |
| 2002 Q2 | -208 Thousand USD | -104.81% |
| 2002 Q4 | -107 Thousand USD | 89.11% |
| 2002 FY | -1.29 Million USD | 84.73% |
| 2002 Q1 | 4.32 Million USD | 890.86% |
| 2001 FY | -8.47 Million USD | -722.78% |
| 2001 Q3 | -1.67 Million USD | 69.91% |
| 2001 Q2 | -5.55 Million USD | -693.86% |
| 2001 Q1 | -700 Thousand USD | -331.79% |
| 2001 Q4 | -547 Thousand USD | 67.28% |
| 2000 Q4 | 302 Thousand USD | -25.06% |
| 2000 Q3 | 403 Thousand USD | 7.75% |
| 2000 FY | 1.36 Million USD | -51.39% |
| 2000 Q2 | 374 Thousand USD | 32.62% |
| 2000 Q1 | 282 Thousand USD | -74.36% |
| 1999 Q3 | 800 Thousand USD | 100.0% |
| 1999 FY | 2.8 Million USD | 340.94% |
| 1999 Q2 | 400 Thousand USD | -33.33% |
| 1999 Q1 | 600 Thousand USD | 155.32% |
| 1999 Q4 | 1.1 Million USD | 37.5% |
| 1998 FY | 635 Thousand USD | 150.0% |
| 1998 Q1 | -200 Thousand USD | -766.67% |
| 1998 Q2 | 200 Thousand USD | 200.0% |
| 1998 Q3 | 300 Thousand USD | 50.0% |
| 1998 Q4 | 235 Thousand USD | -21.67% |
| 1997 Q4 | 30 Thousand USD | 104.29% |
| 1997 Q1 | -400 Thousand USD | -640.74% |
| 1997 FY | -1.27 Million USD | -2860.87% |
| 1997 Q2 | -300 Thousand USD | 25.0% |
| 1997 Q3 | -700 Thousand USD | -133.33% |
| 1996 Q3 | 200 Thousand USD | 100.0% |
| 1996 Q4 | -54 Thousand USD | -127.0% |
| 1996 Q1 | -200 Thousand USD | 97.26% |
| 1996 FY | 46 Thousand USD | 100.68% |
| 1996 Q2 | 100 Thousand USD | 150.0% |
| 1995 Q4 | -7.3 Million USD | -3750.0% |
| 1995 Q1 | 100 Thousand USD | -66.67% |
| 1995 Q2 | 200 Thousand USD | 100.0% |
| 1995 Q3 | 200 Thousand USD | 0.0% |
| 1995 FY | -6.8 Million USD | -6900.0% |
| 1994 Q3 | 100 Thousand USD | 200.0% |
| 1994 Q4 | 300 Thousand USD | 200.0% |
| 1994 Q2 | -100 Thousand USD | 50.0% |
| 1994 Q1 | -200 Thousand USD | 71.43% |
| 1994 FY | 100 Thousand USD | 102.56% |
| 1993 Q1 | 700 Thousand USD | 40.0% |
| 1993 Q2 | -100 Thousand USD | -114.29% |
| 1993 Q3 | -3.4 Million USD | -3300.0% |
| 1993 Q4 | -700 Thousand USD | 79.41% |
| 1993 FY | -3.9 Million USD | -269.57% |
| 1992 Q3 | 500 Thousand USD | -28.57% |
| 1992 Q1 | 600 Thousand USD | -14.29% |
| 1992 Q2 | 700 Thousand USD | 16.67% |
| 1992 FY | 2.3 Million USD | 35.29% |
| 1992 Q4 | 500 Thousand USD | 0.0% |
| 1991 FY | 1.7 Million USD | 325.0% |
| 1991 Q1 | 100 Thousand USD | 0.0% |
| 1991 Q2 | 200 Thousand USD | 100.0% |
| 1991 Q3 | 600 Thousand USD | 200.0% |
| 1991 Q4 | 700 Thousand USD | 16.67% |
| 1990 Q3 | 100 Thousand USD | 0.0% |
| 1990 Q4 | 100 Thousand USD | 0.0% |
| 1990 Q2 | 100 Thousand USD | 0.0% |
| 1990 Q1 | 100 Thousand USD | 133.33% |
| 1990 FY | 400 Thousand USD | 144.44% |
| 1989 Q1 | -200 Thousand USD | 0.0% |
| 1989 Q3 | -200 Thousand USD | 0.0% |
| 1989 Q4 | -300 Thousand USD | -50.0% |
| 1989 FY | -900 Thousand USD | 0.0% |
| 1989 Q2 | -200 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | 159.936% |
| Arrayit Corporation | -3.31 Million USD | 125.489% |
| Atlantic International Corp. | -5.62 Million USD | 115.017% |
| Biocept, Inc. | -32.08 Million USD | 102.634% |
| Bioqual, Inc. | 483.48 Thousand USD | -74.795% |
| CardioGenics Holdings Inc | -1.91 Million USD | 144.1% |
| DermTech, Inc. | -100.88 Million USD | 100.838% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 99.958% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 103.914% |
| iMD Companies, Inc. | -200.63 Thousand USD | 521.212% |
| IDenta Corp. | 14.64 Thousand USD | -5670.978% |
| Interpace Biosciences, Inc. | 802 Thousand USD | -5.374% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | -2084.347% |
| InVitro International | 1553.00 USD | -54317.386% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 109.836% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 1554.264% |
| Medical Imaging Corp. | -3.02 Million USD | 127.956% |
| NovelStem International Corp. | -4.18 Million USD | 120.183% |
| Optigenex Inc. | -2.89 Million USD | 129.164% |
| Proteome Sciences plc | -2.44 Million USD | 134.593% |
| Response Genetics, Inc | -20.18 Million USD | 104.187% |
| Rennova Health, Inc. | -3.29 Million USD | 125.663% |
| RushNet, Inc. | -607.02 Thousand USD | 239.22% |
| ScreenPro Security Inc. | -2.24 Million USD | 137.581% |
| Stella Diagnostics Inc. | -5.7 Million USD | 114.807% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 107.403% |
| Todos Medical Ltd. | -24.99 Million USD | 103.381% |